Amplia

Be first to know our latest company updates

Watch exclusive videos accompanying major news

Science

Contact

Board

Company Overview

Team

Corporate Governance

Corporate Directory

Values

Clinical Advisers

About Us

Video Updates

Presentations

In the News

Communication

Updates

US Shareholders

Investor FAQs

Shareholder Services

Research Reports

Reports

Announcements

Investor Fact Sheet

Top 20 Shareholders

Share Price

Investor Centre

Clinical Trial

Webinars

Home

Montserrat

Amplia Therapeutics Limited

upload.jpg

Amplia has announced the opening of two Australian clinical trial sites for the Company’s new pancreatic cancer study.

This new trial explores the combination of the Company’s best-in-class FAK inhibitor narmafotinib with the chemotherapy FOLFIRINOX in newly diagnosed metastatic pancreatic cancer patients.

Recruitment of patients has now commenced at trial sites in Melbourne and Sydney, with dosing of patients to be reported in due course. Clinical trial sites in the US have already been identified and will be open for patient recruitment in the coming weeks.

Dr Chris Burns, Amplia’s CEO and Managing Director commented:

“We are excited to have the first clinical trial sites for this new pancreatic cancer trial now open in Australia. Based on the promising data from the existing ACCENT trial, and our preclinical studies, we believe that the combination of narmafotinib and FOLFIRINOX has potential to improve patient outcomes in this challenging disease.”

Australian Trial Sites Open for New Narmafotinib Combination Trial